Gaviscon Liquid Aniseed Flavour
- Name:
Gaviscon Liquid Aniseed Flavour
- Company:
Reckitt Benckiser Ireland Limited
- Active Ingredients:
- Legal Category:
Supply through general sale
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/01/20


Print ViewKeyword Search SPC
1. NAME OF THE MEDICINAL PRODUCT
1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4. CLINICAL PARTICULARS
5. PHARMACOLOGICAL PROPERTIES
5. PHARMACOLOGICAL PROPERTIES
6. PHARMACEUTICAL PARTICULARS
6. PHARMACEUTICAL PARTICULARS
7. MARKETING AUTHORISATION HOLDER
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT
10. DATE OF REVISION OF THE TEXT
Reckitt Benckiser Ireland Limited

Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 15 January 2020 PIL
Reasons for updating
- New PIL for new product
Updated on 14 June 2016 SPC
Reasons for updating
- New SPC for new product
Legal category: Supply through general sale
Updated on 14 June 2016 SPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 14 June 2016 PIL
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
Free text change information supplied by the pharmaceutical company
Updated on 19 April 2016 SPC
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 19 April 2016 PIL
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Free text change information supplied by the pharmaceutical company
Updated on 8 September 2014 PIL
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section 4.4 - Added that if symptoms persist after 7 days to consult a doctor. Added additional warnings regarding excipients.
Section 4.5 - Added a time interval between taking Gaviscon and other products.
Section 4.6 - Added specific information to each category Pregnancy, Breast-feeding, and Fertility
Section 4.7 - Changed wording.
Section 4.8 - The format has changed. Added information on how to report suspected adverse events.
Section 10 - Updated the date of revision of the text.
Updated on 8 September 2014 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.4 - Added that if symptoms persist after 7 days to consult a doctor. Added additional warnings regarding excipients.
Section 4.5 - Added a time interval between taking Gaviscon and other products.
Section 4.6 - Added specific information to each category Pregnancy, Breast-feeding, and Fertility
Section 4.7 - Changed wording.
Section 4.8 - The format has changed. Added information on how to report suspected adverse events.
Section 10 - Updated the date of revision of the text.
Updated on 13 December 2012 PIL
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Free text change information supplied by the pharmaceutical company
Updated on 13 December 2012 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 15 May 2007 PIL
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
Updated on 15 May 2007 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.8 - Undesirable effects
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 9 August 2006 PIL
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
Free text change information supplied by the pharmaceutical company
Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5. Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.
Reduction in shelf-life from three years to two years in section 6.3
Updated on 9 August 2006 SPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5. Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.
Reduction in shelf-life from three years to two years in section 6.3
Updated on 19 May 2005 PIL
Reasons for updating
- Improved electronic presentation
Updated on 19 May 2005 SPC
Reasons for updating
- Improved electronic presentation
Legal category: Supply through general sale
Updated on 10 August 2004 SPC
Reasons for updating
- Improved electronic presentation
Legal category: Supply through general sale
Updated on 10 August 2004 PIL
Reasons for updating
- Improved electronic presentation
Updated on 20 August 2003 PIL
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
Updated on 20 August 2003 SPC
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
Legal category: Supply through general sale
Updated on 16 June 2003 SPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Supply through general sale
Updated on 16 June 2003 PIL
Reasons for updating
- New SPC for medicines.ie